Strategic partnerships STC Biologics specializes in partnering with pharmaceutical and biotechnology companies to accelerate drug development, offering analytics driven process development and support across target selection to IND/CTA filing and BLA/MAA.

Biosimilar focus With a core emphasis on biologics and biosimilar development, STC Biologics presents opportunities for collaborations in biosimilar programs, process development optimization, and analytics-driven manufacturing readiness.

Speed to clinic Their Speed-To-Clinic Platform for monoclonal antibodies enables rapid progression from royalty-free cell line development to cGMP manufacturing and released drug substance within twelve months, a strong selling point for fast-track programs.

Recent collaboration signal Publicized partnership with Tiziana Life Sciences for manufacturing TZLS-501 indicates openness to external collaborations and potential for expanded CDMO-style engagements in clinical trial material production.

Mid-market fit Company size and revenue place STC Biologics in a mid-tier segment compatible with mid-sized biotech or specialty pharma partners seeking specialized analytics driven development without the scale of mega-CDMOs.